Table 3 Associations between patient factors and CRRM rates.

From: The Angelina Jolie effect: Contralateral risk-reducing mastectomy trends in patients at increased risk of breast cancer

  N CRRM rate p value
Age at breast cancer (years)    < 0.001*
< 45 132 64 (48.5%)  
45–49 109 33 (30.3%)  
50–54 75 18 (24.0%)  
55 +  70 8 (11.4%)  
Estimated lifetime risk (%)    < 0.001*
< 30% 122 17 (13.9%)  
30–39% 101 27 (26.7%)  
40+% 163 79 (48.5%)  
Risk category**    < 0.001
Moderate 117 17 (14.5%)  
High (non-BRCA) 163 47 (28.8%)  
BRCA1 54 29 (53.7%)  
BRCA2 50 30 (60.0%)  
Pathology    0.509
IDC 276 84 (30.4%)  
ILC 30 9 (30.0%)  
Mixed IC 4 1 (25.0%)  
Pre-Invasive 71 28 (39.4%)  
Size category    0.793
Invasive: 0–19 mm 212 64 (30.2%)  
Invasive: 20+ mm 92 29 (31.5%)  
In-situ: 0–19 mm 39 14 (35.9%)  
In-situ: 20 mm 24 9 (37.5%)  
Grade    0.015
Grade 1 44 6 (13.6%)  
Grade 2 119 36 (30.3%)  
Grade 3 144 52 (36.1%)  
Carcinoma in-situ 71 28 (39.4%)  
Lymph node status (pathological)    0.196*
Negative 239 77 (32.2%)  
1–3 nodes Positive 72 19 (26.4%)  
> 3 nodes Positive 12 2 (16.7%)  
TNM stage    0.040*
Stage 0 68 28 (41.2%)  
Stage 1 188 61 (32.4%)  
Stage 2 107 30 (28.0%)  
Stage 3 16 3 (18.8%)  
Molecular subtype    0.327
Luminal A 238 72 (30.3%)  
Luminal B 10 2 (20.0%)  
Triple Negative 89 34 (38.2%)  
HER2 enriched 6 3 (50.0%)  
  1. Data are reported as N (row %), with p values from Fisher’s exact tests, unless stated otherwise. Bold p values are significant at p < 0.05. *p value from Mann–Whitney U test, as the factor is ordinal. **Excludes N = 1 with both BRCA1 and BRCA2 mutations. IDC invasive ductal carcinoma, ILC Invasive Lobular carcinoma, IC invasive carcinoma.